

## PE anti-mouse CD335 (NKp46) Antibody

<b>Catalog# / Size</b>	137603 / 25 µg 137604 / 100 µg
<b>Clone</b>	29A1.4
<b>Regulatory Status</b>	RUO
<b>Other Names</b>	NKp46, NCR1
<b>Isotype</b>	Rat IgG2a, κ
<b>Description</b>	CD335, also known as NKp46, is a single-pass type I membrane protein of 46 kD. It belongs to the natural cytotoxicity receptor (NCR) family and contains two Ig-like (immunoglobulin-like) domains. It's expression is restricted to NK cells and a subset of NKT cells; it's not expressed in CD1d-restricted NKT cells. CD335 is a receptor for viral hemagglutinins and heparan sulfate proteoglycans and is involved in NK cell activation.

### Product Details

---

<b>Verified Reactivity</b>	Mouse
<b>Antibody Type</b>	Monoclonal
<b>Host Species</b>	Rat
<b>Immunogen</b>	NKP46-IgG1 Fc fusion protein
<b>Formulation</b>	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
<b>Preparation</b>	The antibody was purified by affinity chromatography, and conjugated with PE under optimal conditions.
<b>Concentration</b>	0.2 mg/ml
<b>Storage &amp; Handling</b>	The antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. <b>Do not freeze.</b>
<b>Application</b>	<a href="#">FC - Quality tested</a>
<b>Recommended Usage</b>	Each lot of this antibody is quality control tested by <a href="#">immunofluorescent staining with flow cytometric analysis</a> . For flow cytometric staining, the suggested use of this reagent is ≤1.0 µg per million cells in 100 µl volume. It is recommended that the reagent be titrated for optimal performance for each application.
<b>Excitation Laser</b>	Blue Laser (488 nm) Green Laser (532 nm)/Yellow-Green Laser (561 nm)
<b>Application Notes</b>	Additional reported applications (for the relevant formats) include: immunohistochemical staining of frozen tissue sections <sup>1,2</sup> and <i>in vitro</i> activation of NK cells <sup>1</sup> .
<b>Application References</b>	1. Walzer T, <i>et al.</i> 2007. <i>P. Natl. Acad. Sci. USA</i> 104:3384. (FC, Activ) 2. Walzer T, <i>et al.</i> 2007. <i>Nat. Immunol.</i> 8:1337. (FC, Activ) 3. Guerriero JL, <i>et al.</i> 2011. <i>J. Immunol.</i> 186:3517. (IHC) <a href="#">PubMed</a>
<b>(PubMed link indicates BioLegend citation)</b>	
<b>Product Citations</b>	1. Palacios-Arreola M, <i>et al.</i> 2017. <i>Sci Rep.</i> 10.1038/s41598-017-10135-1. <a href="#">PubMed</a> 2. Vogt M, <i>et al.</i> 2011. <i>J Virol.</i> 85:11567. <a href="#">PubMed</a> 3. Fu R, <i>et al.</i> 2020. <i>Sci Rep.</i> 10:1455. <a href="#">PubMed</a> 4. Cluff E, <i>et al.</i> 2022. <i>Cancer Immunol Immunother.</i> . <a href="#">PubMed</a> 5. Almeida AS, <i>et al.</i> 2021. <i>Bio Protoc.</i> 11:e4012. <a href="#">PubMed</a> 6. Li Y, <i>et al.</i> 2014. <i>PLoS One.</i> 9:86927. <a href="#">PubMed</a> 7. Fu B <i>et al.</i> 2017. <i>Immunity.</i> 47(6):1100-1113 . <a href="#">PubMed</a> 8. Victorino F, <i>et al.</i> 2015. <i>J Immunol.</i> 195: 4973 - 4985. <a href="#">PubMed</a> 9. Dolgova EV, <i>et al.</i> 2022. <i>Int J Mol Sci.</i> 23:. <a href="#">PubMed</a> 10. Starkl P, <i>et al.</i> 2020. <i>Immunity.</i> 53(4):793-804.e9. <a href="#">PubMed</a>

11. Fachi JL, *et al.* 2020. *J Exp Med.* 217:00:00. [PubMed](#)
12. Best SA, *et al.* 2018. *Cell Metab.* 27:935. [PubMed](#)
13. Almeida AS, *et al.* 2021. *Bio Protoc.* 11:e4012. [PubMed](#)
14. Li J, *et al.* 2020. *Cancer Discov.* . [PubMed](#)
15. Schaffert A, *et al.* 2020. *Front Immunol.* 10:3024. [PubMed](#)
16. Li J, *et al.* 2020. *Cancer Immunol Res.* 0.529166667. [PubMed](#)
17. Adams NM *et al.* 2018. *Immunity.* 48(6):1172-1182 . [PubMed](#)
18. Progzatzky F, *et al.* 2021. *Nature.* 599:125. [PubMed](#)
19. Wiedemann GM, *et al.* 2020. *Cell Rep.* 33:108498. [PubMed](#)
20. Diaz-Salazar C, *et al.* 2020. *Cell Rep.* 32:108186. [PubMed](#)
21. Ye X, *et al.* 2021. *Cancer Biol Med.* Online ahead of print. [PubMed](#)
22. Ruiz-Manzano RA, *et al.* 2020. *Frontiers in Oncology.* 0.927777778. [PubMed](#)
23. Yuan X, *et al.* 2017. *Elife.* 6:e29540. [PubMed](#)
24. Kang YH, *et al.* 2019. *Nat Commun.* 10:912. [PubMed](#)
25. Zhao L, *et al.* 2017. *Nat Commun.* . 10.1038/s41467-017-01181-4. [PubMed](#)
26. Sheppard S, *et al.* 2021. *Cell Reports.* 35(9):109210. [PubMed](#)
27. Teng F, *et al.* 2021. *Cell Rep.* 37:110051. [PubMed](#)
28. Geary CD *et al.* 2018. *Cell reports.* 24(8):1949-1957 . [PubMed](#)
29. Liu CF, *et al.* 2017. *Front Immunol.* 1.445833333. [PubMed](#)
30. Guo S, *et al.* 2021. *Frontiers in Immunology.* 11:614667. [PubMed](#)

**RRID** AB\_10552741 (BioLegend Cat. No. 137603)  
 AB\_2235755 (BioLegend Cat. No. 137604)

## Antigen Details

---

<b>Structure</b>	Single-pass type I membrane protein, 46 kD; belongs to the natural cytotoxicity receptor (NCR) family; contains 2 Ig-like (immunoglobulin-like) domains
<b>Distribution</b>	Mature and immature NK cells, subset of NKT cells, but not on CD1d-restricted NKT cells
<b>Function</b>	NK cells activation
<b>Ligand/Receptor</b>	Viral hemagglutinins, heparan sulfate proteoglycans
<b>Cell Type</b>	NK cells, NKT cells
<b>Biology Area</b>	Immunology, Innate Immunity
<b>Molecular Family</b>	CD Molecules
<b>Antigen References</b>	<ol style="list-style-type: none"> <li>1. Colucci F and Cilio CM. 2010. <i>Nat. Immunol.</i> 125:60.</li> <li>2. Caligiuri MA. 2008. <i>Blood</i> 112:461.</li> <li>3. Colonna M. 2009. <i>Immunity</i> 31:15.</li> </ol>
<b>Gene ID</b>	<a href="#">17086</a>

## Related Protocols

---

[Cell Surface Flow Cytometry Staining Protocol](#)

## Other Formats


---

Brilliant Violet 510™ anti-mouse CD335 (NKp46), Brilliant Violet 711™ anti-mouse CD335 (NKp46), PE anti-mouse CD335 (NKp46), PE/Cyanine7 anti-mouse CD335 (NKp46), Purified anti-mouse CD335 (NKp46), FITC anti-mouse CD335 (NKp46), APC anti-mouse CD335 (NKp46), PerCP/Cyanine5.5 anti-mouse CD335 (NKp46), Brilliant Violet 421™ anti-mouse CD335 (NKp46), Biotin anti-mouse CD335 (NKp46), Brilliant Violet 605™ anti-mouse CD335 (NKp46), Purified anti-mouse CD335 (NKp46) (Maxpar® Ready), Alexa Fluor® 647 anti-mouse CD335 (NKp46), PE/Dazzle™ 594 anti-mouse CD335 (NKp46), APC/Fire™ 750 anti-mouse CD335 (NKp46), Brilliant Violet 650™ anti-mouse CD335 (NKp46), TotalSeq™-A0184 anti-mouse CD335 (NKp46), Brilliant Violet 785™ anti-mouse CD335 (NKp46), Ultra-LEAF™ Purified anti-mouse CD335 (NKp46), TotalSeq™-B0184 anti-mouse CD335 (NKp46), TotalSeq™-C0184 anti-mouse CD335 (NKp46), APC/Cyanine7 anti-mouse CD335 (NKp46), PE/Cyanine5 anti-mouse CD335 (NKp46)

## Product Data

---

C57BL/6 mouse splenocytes stained  
with 29A1.4 PE and NK1.1 (PK136) APC



For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

\*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, [www.biolegend.com/ordering#license](http://www.biolegend.com/ordering#license)). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

BioLegend Inc., 8999 BioLegend Way, San Diego, CA 92121 [www.biolegend.com](http://www.biolegend.com)  
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587